On the one hand, MEHPPs have the ability to inhibite α‐amylase and α‐glucosidase activities and decrease postprandial blood glucose; on the other hand, MEHPPs enhance insulin sensitivity, regulating insulin signaling and improving insulin resistance via downregulating PTP1B expression and regulating PI3K‐AKT/GSK3β/FoxO1 signaling pathway. The gene discussed is AKT1; the disease is Insulin resistance.